A randomized trial in women with ER-positive breast cancer found that low dose tamoxifen (1 or 5 mg) can decrease tumor proliferation, as measured by Ki-67 expression, comparable to that of high dose tamoxifen (20 mg) (59). The gene discussed is MKI67; the disease is neoplasm.